Literature DB >> 26310579

Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.

Jong R Kim1, Stephen O Mathew1, Porunelloor A Mathew2.   

Abstract

CS1 (CRACC/CD319/SLAMF7) is a member of SLAM (Signaling Lymphocyte Activation Molecule) family receptors and is expressed on NK cells, a subset of CD8(+) T lymphocytes, activated monocytes, mature dendritic cells and activated B cells. In NK cells, CS1 signaling induces cytolytic function of NK cells against targets whereas in B cells CS1 induces proliferation and autocrine cytokine production. CS1 is upregulated in multiple myeloma cells and contributes to clonogenic growth and tumorigenicity. However, the mechanism of CS1 upregulation is unknown. In this study, we analyzed the transcriptional regulation of human CS1 gene in NK and B cells. The promoter region of CS1 contains a Blimp-1/PRDM1 binding site and relative luciferase activities of successive deletion mutants of CS1 promoter were different between Blimp-1/PRDM1-positive and Blimp-1/PRDM1-negative cells. Proximal region of CS1 promoter contains a CAAT box and atypical TATA-box that might result in common transcription initiation at -29 nucleotides upstream of the ATG translation start codon. Electrophoretic Mobility Shift Assay (EMSA) and Chromatin Immunoprecipitation (ChIP) assays revealed Blimp-1/PRDM1 binds to the CS1 promoter region. Mutating the Blimp-1/PRDM1 site at -750 to -746 decreased the transcriptional activity of CS1 promoter implicating a trans-activating function of Blimp-1/PRDM1 in human CS1 gene regulation. The finding that Blimp-1/PRDM1 enhances transcription of CS1 gene in multiple myeloma cells may help in developing novel strategies for therapeutic intervention in multiple myeloma.
Copyright © 2015. Published by Elsevier GmbH.

Entities:  

Keywords:  B cells; Blimp-1/PRDM1; CS1; NK cells

Mesh:

Substances:

Year:  2015        PMID: 26310579     DOI: 10.1016/j.imbio.2015.08.005

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  13 in total

1.  Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.

Authors:  Jiro Kikuchi; Mitsuo Hori; Hidekatsu Iha; Noriko Toyama-Sorimachi; Shotaro Hagiwara; Yoshiaki Kuroda; Daisuke Koyama; Tohru Izumi; Hiroshi Yasui; Atsushi Suzuki; Yusuke Furukawa
Journal:  Leukemia       Date:  2019-07-29       Impact factor: 11.528

2.  Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.

Authors:  Jutatip Panaampon; Ryusho Kariya; Seiji Okada
Journal:  Cancer Immunol Immunother       Date:  2022-03-09       Impact factor: 6.630

3.  SLAMF7 engagement superactivates macrophages in acute and chronic inflammation.

Authors:  Daimon P Simmons; Hung N Nguyen; Emma Gomez-Rivas; Yunju Jeong; A Helena Jonsson; Antonia F Chen; Jeffrey K Lange; George S Dyer; Philip Blazar; Brandon E Earp; Jonathan S Coblyn; Elena M Massarotti; Jeffrey A Sparks; Derrick J Todd; Deepak A Rao; Edy Y Kim; Michael B Brenner
Journal:  Sci Immunol       Date:  2022-02-11

Review 4.  CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Authors:  Joseph D Malaer; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

5.  SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment.

Authors:  Patrick O'Connell; Sean Hyslop; Maja K Blake; Sarah Godbehere; Andrea Amalfitano; Yasser A Aldhamen
Journal:  J Immunol       Date:  2020-12-07       Impact factor: 5.422

Review 6.  Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.

Authors:  Alessandra Romano; Paola Storti; Valentina Marchica; Grazia Scandura; Laura Notarfranchi; Luisa Craviotto; Francesco Di Raimondo; Nicola Giuliani
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

Review 7.  Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Authors:  Masafumi Taniwaki; Mihoko Yoshida; Yosuke Matsumoto; Kazuho Shimura; Junya Kuroda; Hiroto Kaneko
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-02-15       Impact factor: 2.576

8.  The LL-100 panel: 100 cell lines for blood cancer studies.

Authors:  Hilmar Quentmeier; Claudia Pommerenke; Wilhelm G Dirks; Sonja Eberth; Max Koeppel; Roderick A F MacLeod; Stefan Nagel; Klaus Steube; Cord C Uphoff; Hans G Drexler
Journal:  Sci Rep       Date:  2019-06-03       Impact factor: 4.379

9.  PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients.

Authors:  Gabriele Buda; Francesca Guerrini; Sara Galimberti; Enrico Orciuolo; Simone Pacini; Elisa Mazzantini; Mario Petrini
Journal:  Hematol Rep       Date:  2017-12-22

10.  Association of circulating SLAMF7+Tfh1 cells with IgG4 levels in patients with IgG4-related disease.

Authors:  Kazuhiko Higashioka; Yuri Ota; Takashi Maehara; Masafumi Moriyama; Masahiro Ayano; Hiroki Mitoma; Mitsuteru Akahoshi; Yojiro Arinobu; Takahiko Horiuchi; Seiji Nakamura; Koichi Akashi; Hiroaki Niiro
Journal:  BMC Immunol       Date:  2020-06-01       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.